Investors Encouraged to Take Lead in Inovio Pharmaceuticals Securities Fraud Case

Investors in Inovio Pharmaceuticals, Inc. are presented with a chance to take the lead in a securities fraud lawsuit with the Schall Law Firm. The firm recently announced that it is encouraging investors who purchased Inovio securities between February 14, 2020, and February 28, 2021, to join the lawsuit. This legal action focuses on whether Inovio and certain of its executives made false and misleading statements or failed to disclose information related to the company’s development of its COVID-19 vaccine candidate.

The lawsuit alleges that Inovio made misleading statements regarding the development and regulatory approval process for its COVID-19 vaccine candidate. The company claimed that it had designed a proprietary device to deliver the vaccine efficiently when, in fact, Inovio was relying on a third-party manufacturer for the device. Additionally, Inovio stated that it was on track to begin clinical trials for the vaccine in the summer of 2020, but the company later disclosed that it had not received regulatory clearance to commence the trials.

Inovio also faces allegations that it made false and misleading statements about the company’s involvement in Operation Warp Speed, the U.S. government’s program to accelerate the development and distribution of COVID-19 vaccines. The lawsuit contends that Inovio failed to disclose that it was not part of the program and therefore did not receive funding or support from Operation Warp Speed.

The Schall Law Firm is actively investigating these claims and is seeking to determine whether Inovio and its executives violated federal securities laws. If investors are interested in participating in the lawsuit, they are encouraged to contact the Schall Law Firm. The firm specializes in securities litigation and has a track record of success in holding companies accountable for misleading investors.

Investors who purchased Inovio securities during the specified time period and have suffered financial losses as a result of these alleged misrepresentations may be eligible to join the lawsuit. By taking a proactive approach and seeking legal recourse, investors have the opportunity to potentially recover their losses and hold Inovio accountable for any wrongdoing.

Overall, the securities fraud lawsuit against Inovio Pharmaceuticals, Inc. presents investors with the chance to take action in response to alleged false and misleading statements made by the company. The Schall Law Firm is dedicated to representing investors who have been harmed by securities fraud and is committed to seeking justice on their behalf. Investors who have been affected by the alleged misconduct are encouraged to reach out to the Schall Law Firm to learn more about their legal options.